Most Read Articles
18 Sep 2017
Use of dipeptidyl peptidase 4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus is associated with a lower incidence of gastrointestinal adverse events compared with glucagon-like peptide 1 receptor agonists, metformin and alpha-glucosidase inhibitors, according to a study.
08 May 2020
Hydroxychloroquine appears to have more potent in vitro anti-SARS-CoV-2 activity than chloroquine, as shown in a study.
Roshini Claire Anthony, 26 Nov 2019

The anti-inflammatory drug colchicine at a dose of 0.5 mg/day significantly reduced the risk of ischaemic cardiovascular (CV) events in individuals with a recent myocardial infarction (MI), according to results of the COLCOT* trial presented at AHA 2019.

Audrey Abella, 09 Apr 2020
The human monoclonal anti-IGF-1R* antibody teprotumumab was effective in reducing proptosis or eye bulging in patients with the rare thyroid eye disease (TED) regardless of age, gender, and/or smoking status, according to pooled data presented at ENDO 2020.

Product Highlight - Tationil 600

30 Apr 2020
Reduces toxicity to improve quality of life

Indication:
Used to alleviate the manifestation of toxicity brought by Cisplatin chemotherapy.

Reference:
*Tationil 600 Full Prescribing Information

Further information is available in MIMS section 3b.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Philippines digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Sep 2017
Use of dipeptidyl peptidase 4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus is associated with a lower incidence of gastrointestinal adverse events compared with glucagon-like peptide 1 receptor agonists, metformin and alpha-glucosidase inhibitors, according to a study.
08 May 2020
Hydroxychloroquine appears to have more potent in vitro anti-SARS-CoV-2 activity than chloroquine, as shown in a study.
Roshini Claire Anthony, 26 Nov 2019

The anti-inflammatory drug colchicine at a dose of 0.5 mg/day significantly reduced the risk of ischaemic cardiovascular (CV) events in individuals with a recent myocardial infarction (MI), according to results of the COLCOT* trial presented at AHA 2019.

Audrey Abella, 09 Apr 2020
The human monoclonal anti-IGF-1R* antibody teprotumumab was effective in reducing proptosis or eye bulging in patients with the rare thyroid eye disease (TED) regardless of age, gender, and/or smoking status, according to pooled data presented at ENDO 2020.